Drugs / NK1R+ MSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05491681 | Jan 2026 | acute respiratory distress syndrome | BioCardia, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NK1R+ MSC | “The NK1R+ MSC cell therapy are allogeneic bone marrow-derived mesenchymal stem cells that will be delivered intravenously.” NCT05491681 ↗ |
| Modality | Cell therapy | “The NK1R+ MSC cell therapy are allogeneic bone marrow-derived mesenchymal stem cells” NCT05491681 ↗ |
| Route | Intravenous | “will be delivered intravenously.” NCT05491681 ↗ |